Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States-Reference-Cited by-同舟云学术

Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States

Published:2016-09-07 Issue:1 Volume:20 Page:63-71
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Latremouille-Viau Dominick¹,Guerin Annie¹,Nitulescu Roy¹,Gagnon Patrick S.¹,Joseph George J.²,Chen Lei²

Affiliation:

1. Analysis Group, Inc., Montreal, QC, Canada;

2. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1225578

Reference29 articles.

1. NIH National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER) stat fact sheets: Chronic Myeloid Leukemia (CML) [Internet]. 2016. http://seer.cancer.gov/statfacts/html/cmyl.html. Accessed June 6, 2016

2. Philadelphia ChromosomePositive Leukemias: From Basic Mechanisms to Molecular Therapeutics

3. Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

4. Molecular biology of bcr-abl1–positive chronic myeloid leukemia

5. Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Asciminib - ABL Kinase Inhibitor in the Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia: Chemistry and Pharmacology Perspectives;Mini-Reviews in Organic Chemistry;2023-10-17

2. Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults;Expert Opinion on Pharmacotherapy;2023-07-27

3. Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States;Journal of Health Economics and Outcomes Research;2022-08-04

4. Chronic Myeloid Leukemia: Part I—Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States;Journal of Health Economics and Outcomes Research;2022-08-04

5. The Impact of Urate‐Lowering Therapy in Post‐Myocardial Infarction Patients: Insights From a Population‐Based, Propensity Score‐Matched Analysis;Clinical Pharmacology & Therapeutics;2021-11-17